Advertisement

Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis

  • Lopamudra Kirtania
  • Rituparna MaitiEmail author
  • Anand Srinivasan
  • Archana Mishra
Systematic Review
  • 12 Downloads

Abstract

Background

The combination of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor having different biological targets has become an integral part of the treatment of pulmonary arterial hypertension; however, several clinical studies have reported conflicting results.

Objective

The objective of this meta-analysis was to evaluate the effect of an endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination in pulmonary arterial hypertension.

Methods

After performing a comprehensive literature search in MEDLINE, Cochrane and the International Clinical Trial Registry Platform, reviewers assessed eligibility and extracted data from seven relevant articles (publications till December 2018). PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed in the selection, analysis and reporting of findings. The odds ratio and mean difference were calculated to estimate the difference in clinical worsening, 6-minute walking distance, pulmonary vascular resistance and N-terminal pro-brain natriuretic peptide between the groups. Quality assessment was performed using the risk of bias assessment tool and a meta-regression for probable variables affecting effect size.

Results

The random-effect model analysis revealed an odds ratio of 0.56 [95% confidence interval (CI) 0.41–0.76; p = 0.0002] for clinical worsening, mean difference of 15.64 (95% CI 2.67–28.61; p = 0.02) for 6-minute walking distance, − 1.66 (95% CI − 3.82 to 0.50; p = 0.13) for pulmonary vascular resistance and − 21.04 (95% CI − 26.87 to − 15.22; p < 0.00001) for N-terminal pro-brain natriuretic peptide. The meta-regression showed no statistically significant association between the dose and duration of treatment and outcomes (odds ratio of clinical worsening and mean difference of 6-minute walking distance).

Conclusions

In pulmonary arterial hypertension, endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination therapy significantly improved 6-minute walking distance, clinical worsening and N-terminal pro-brain natriuretic peptide compared with the monotherapy but did not offer any advantage in improving pulmonary vascular resistance.

PROSPERO Registration No

CRD42018091133.

Notes

Compliance with Ethical Standards

Funding

No funding was received to conduct this meta-analysis.

Conflict of interest

Lopamudra Kirtania, Rituparna Maiti, Anand Srinivasan and Archana Mishra have no conflicts of interest that are directly relevant to the content of this article.

Author contributions

LK, RM and AM contributed substantially to the study design, protocol writing and registration, data extraction, data analysis, interpretation and the writing of the manuscript. AS contributed to the study design, data analysis, and interpretation, and revised the manuscript critically for important intellectual content. All authors gave final approval of the version to be published.

References

  1. 1.
    Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120(3):157–65.Google Scholar
  2. 2.
    Rivera-Lebron BN, Risbano MG. Ambrisentan: a review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis. 2017;11(6):233–44.Google Scholar
  3. 3.
    Badlam JB, Bull TM. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis. 2017;8(2–3):47–64.Google Scholar
  4. 4.
    Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603–14.Google Scholar
  5. 5.
    Ataya A, Cope J, Alnuaimat H. A review of targeted pulmonary arterial hypertension-specific pharmacotherapy. J Clin Med. 2016;5(12):114.Google Scholar
  6. 6.
    Griffin M, Trow TK. The evolving landscape of combination therapy for pulmonary arterial hypertension. Ther Adv Respir Dis. 2017;11(2):91–5.Google Scholar
  7. 7.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.Google Scholar
  8. 8.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.Google Scholar
  9. 9.
    Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev. 2014;23(134):469–75.Google Scholar
  10. 10.
    Sitbon O, Gaine S. Beyond a single pathway: combination therapy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):408–17.Google Scholar
  11. 11.
    Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord. 2017;17(1):239.Google Scholar
  12. 12.
    van de Veerdonk MC, Huis In TVAE, Marcus JT, Westerhof N, Heymans MW, Bogaard HJ, et al. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. Eur Respir J. 2017;49(6):1700007.Google Scholar
  13. 13.
    Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44.Google Scholar
  14. 14.
    McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405–13.Google Scholar
  15. 15.
    Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res. 2014;37(6):507–12.Google Scholar
  16. 16.
    Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124–31.Google Scholar
  17. 17.
    Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.Google Scholar
  18. 18.
    Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.Google Scholar
  19. 19.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.Google Scholar
  20. 20.
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2011.Google Scholar
  21. 21.
    Manager R. (RevMan) [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.Google Scholar
  22. 22.
    Schwarzer G. Meta: an R package for meta-analysis. R News. 2007;7(3):6.Google Scholar
  23. 23.
    D’Alto M, Romeo E, Argiento P, Paciocco G, Prediletto R, Ghio S, et al. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study). J Cardiovasc Med (Hagerstown). 2018;19(1):12–7 (PubMed PMID: 29215546).Google Scholar
  24. 24.
    Fatima N, Arshad S, Quddusi AI, Rehman A, Nadeem A, Iqbal I. Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension. J Ayub Med Coll Abbottabad. 2018;30(3):333–6 (Epub 2018/11/23.eng).Google Scholar
  25. 25.
    Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, et al. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med. 2017;126:84–92.Google Scholar
  26. 26.
    Hakamata A, Odagiri K, Miyakawa S, Irisawa H, Takeuchi K, Inui N, et al. Pharmacokinetic and pharmacodynamic comparison of sildenafil-bosentan and sildenafil-ambrisentan combination therapies for pulmonary hypertension. Clin Transl Sci. 2016;9(1):29–35.Google Scholar
  27. 27.
    Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jais X, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47(6):1727–36.Google Scholar
  28. 28.
    Legros L, Chabanne C, Camus C, Fournet M, Houssel-Debry P, Latournerie M, et al. Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension. Dig Liver Dis. 2017;49(3):301–7.Google Scholar
  29. 29.
    Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015;46(2):414–21.Google Scholar
  30. 30.
    Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(9):1102–10.Google Scholar
  31. 31.
    Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H. Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension. Res Cardiovasc Med. 2015;4(3):e26487.Google Scholar
  32. 32.
    Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart. 2014;100(3):224–30.Google Scholar
  33. 33.
    Fernandes C, Dias BA, Jardim CVP, Hovnanian A, Hoette S, Morinaga LK, et al. The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. Chest. 2012;141(4):923–8.Google Scholar
  34. 34.
    Sakao S, Tanabe N, Kasahara Y, Tatsumi K. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Intern Med. 2012;51(19):2721–6.Google Scholar
  35. 35.
    Hatano M, Yao A, Kinugawa K, Hirata Y, Nagai R. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. Int Heart J. 2011;52(4):233–9 (Epub 2011/08/11. eng).Google Scholar
  36. 36.
    D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155(3):378–82.Google Scholar
  37. 37.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford). 2010;49(3):490–500.Google Scholar
  38. 38.
    Keogh A, Strange G, Kotlyar E, Williams T, Kilpatrick D, Macdonald P, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J. 2011;41(3):235–44.Google Scholar
  39. 39.
    Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008;15(8):427–30.Google Scholar
  40. 40.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest. 2006;36(Suppl. 3):32–8.Google Scholar
  41. 41.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29(3):469–75.Google Scholar
  42. 42.
    Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004;43(12 Suppl. S):48S–55S.Google Scholar
  43. 43.
    Demir R, Kucukoglu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol. 2015;15(3):249–54 (Epub 2015/04/17.eng).Google Scholar
  44. 44.
    Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27(12):1485–94 (Epub 2006/05/10.eng).Google Scholar
  45. 45.
    Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, et al. Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest. 2017;151(1):90–105.Google Scholar
  46. 46.
    Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Can J Cardiol. 2016;32(12):1520–30.Google Scholar
  47. 47.
    Wang S, Yu M, Zheng X, Dong S. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. Drug Deliv. 2018;25(1):1898–909 (Epub 2018/11/18.eng).Google Scholar
  48. 48.
    Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ. 2017;7(2):312–25.Google Scholar
  49. 49.
    Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145(5):1055–63.Google Scholar
  50. 50.
    Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108(8):1177–82.Google Scholar
  51. 51.
    Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291–305.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacologyAll India Institute of Medical Sciences (AIIMS)BhubaneswarIndia

Personalised recommendations